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Nearly 6% of the adult population within the United States meets criteria for Alcohol Use Disorder 
(AUD) (SAMHSA, 2018). However, few treatments for AUD exist, with no new FDA-approved therapeutic 
agents within the last 15 years. To elucidate mechanisms underlying the neurobiology of AUD, the 
Miles laboratory has used genome-wide expression network profiling of brain regions in mouse 
genetic models following acute and chronic ethanol (EtOH) exposure. These studies identified 
glycogen synthase kinase-3 beta (Gsk3b) as a central member of a gene network highly regulated by 
acute EtOH in medial prefrontal cortex (mPFC) and associated with risk for alcohol dependence in 
humans (Wolen et al., 2012; Putman et al., 2016; van der Vaart et al., 2018).
Further, modulation of Gsk3b via stereotaxic injection of viral vectors alters EtOH consumption in 
rodent models. Viral-mediated overexpression of GSK3B within the mPFC was shown to increase 
EtOH consumption in male mice (Fig 1). Additionally, deletion of Gsk3b decreased EtOH consumption 
and preference in females (Fig 2) (van der Vaart et al., 2018). GSK3B could thus represent a potential new 
therapeutic target for the treatment of alcohol use disorder (AUD). However, the cell type specificity 
for GSK3B’s actions on EtOH consumption have yet to be determined.
Here, we investigate Gsk3b specifically in Camk2a+ neurons in forebrain and its effects on EtOH 
consumption as well as report preclinical evidence for the selective GSK3B inhibitor, tideglusib, as a 
therapeutic agent for AUD.
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HYPOTHESIS
Downregulation of GSK3B, either by deletion in Camk2a+ neurons or 
pharmacological inhibition with tideglusib, will decrease EtOH consumption 
and preference.
SELECTIVE GSK3B DELETION IN Camk2a+ FOREBRAIN NEURONS OR INHIBITION VIA 
TIDEGLUSIB, DECREASES ETHANOL CONSUMPTION IN C57BL/6J MICE
Gsk3b deletion in Camk2a+ cells decreases EtOH consumption and preference 
during both continuous and intermittent EtOH access.
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Fig 2. Viral-mediated deletion of GSK3B in mPFC (A) 
decreases EtOH consumption (g/kg) and (B) preference at 
high EtOH concentrations (van der Vaart, 2018).
Fig 1. Viral-mediated overexpression of GSK3B in mPFC (A) 
increases EtOH consumption (g/kg) at higher EtOH 
concentrations, and (B) increases EtOH preference at 









GSK3B Overexpression GSK3B Deletion
GSK3B inhibition with tideglusib decreases binge (2hr) and daily (24hr) EtOH 
consumption and preference during intermittent EtOH access following 
three weeks of administration.
METHODS
Delete Gsk3b:
• Mouse – male and female transgenic Cre/Gsk3b fl/fl mice (n=5-7 females, 8-10 males per genotype)
• Tamoxifen – dissolved in corn oil at 20mg/ml and injected at 75mg/kg per body weight every 24 hours 
for five days. Control animals only receive corn oil injection
• Drinking – animals given continuous access to 15% w/v EtOH for 15 days, then switched to intermittent 
access for 5 weeks (Fig 3)
Inhibit GSK3B:
• Mouse – male C57BL/6J mice (n=48)
• Tideglusib – dissolved in corn oil at 20mg/ml
and orally gavaged at 100mg/kg twice daily
• Drinking – animals given intermittent access
to 20% v/v EtOH for 3 weeks, then continued
drinking for 4 more weeks during tideglusib
treatment or corn oil control
Fig 3. Schematic of ethanol access in Gsk3b deletion experiment
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Fig 4 . Deletion of Gsk3b significantly decreases EtOH (A) consumption and (B) preference in males during IEA and in
females during continuous access. No main effect of sx or sex*genotype interaction, so sexes were collapsed, revealing a
significant decrease in Cre+ animals in both conditions (*p<0.05) (* p<0.01) (van der Vaart, 2018).
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Fig 6. Arrow denotes beginning of tideglusib treatment. Two Way RM ANOVA revealed: (A) an effect of group (p=0.21),
treatment day (p<0.001), and a significant interaction between the two (p<0.001) for the 2-hour binge reading. Tukey’s
posthoc analysis revealed significant differences between treatment groups during the last week of tideglusib treatment (Day
22 p=0.002; Day 23 p<0.001; Day 24 p<0.001) (B) an effect of treatment day (p<0.001) and a significant interaction between
group x day (p=0.024) for the 24-hour reading. Tukey’s posthoc analysis revealed significant differences between treatment
groups during the last week of tideglusib treatment (Day 23 p<0.001; Day 24 p=0.001).
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Ethanol Preference (%) (2hr) Ethanol Preference (%) (24hr)
EtOH/Vehicle EtOH/Tideglusib EtOH/Vehicle EtOH/Tideglusib
Fig 7. Arrow denotes beginning of tideglusib treatment. Two Way RM ANOVA revealed: (A) an effect of group (p=0.003),
treatment day (p<0.001), and a significant interaction between the two (p<0.001) for the 2-hour binge reading. Tukey’s
posthoc analysis revealed significant differences between treatment groups during the last two weeks of tideglusib treatment
(p<0.05) (B) an effect of group (p=0.032), treatment day (p<0.001) and a significant interaction between the two (p<0.001)
for the 24-hour reading. Tukey’s posthoc analysis revealed significant differences between treatment groups during the last
two weeks of tideglusib treatment (p<0.05).
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These results suggest GSK3B may be a therapeutic target for treatment of AUD. Deletion of Gsk3b 
in forebrain Camk2a-neurons showed a regional and cell-type specificity in GSK3B’s modulation of 
EtOH consumption and preference, providing insight into the mechanisms of Gsk3b action in EtOH 
consumption. Importantly, previous work has shown Gsk3b modulation did not alter basal 
locomotor activity, anxiety-like behavior (light-dark box), taste preference for quinine or saccharin, 
or EtOH pharmacokinetics (Fig 8) (van der Vaart at al, 2018).
Targeting GSK3B using tideglusib, a selective GSK3B inhibitor, also produced a decrease in EtOH 
consumption and preference during week 4 of treatment, though initial gavage decreased total 
fluid consumption in all groups, regardless of EtOH drinking history or tideglusib treatment. Control 
studies showed no effect of tideglusib on liver fat accumulation in EtOH consuming animals.
These findings were consistent with previous work in our lab investigating the delivery of tideglusib 
through intraperitoneal injections (Fig 9), though these studies were limited to a shorter drug-
administration period (van der Vaart, 2018). Here we have used a more therapeutically translatable route of 
administration via oral gavage and begun to investigate the longer-term effects of tideglusib
on EtOH behaviors and toxicity. Tideglusib is a clinically available agent that warrants
investigation in the treatment of AUD.
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Fig 8. Previous work showing: (A) deletion of Gsk3b does not affect anxiety-like behaviors in EtOH naïve or 
24hr abstinence mice or (B) taste preference for quinine or saccharin; and (C) overexpression of Gsk3b does not 
affect EtOH pharmacokinetics (modified from van der Vaart et al, 2018).
Fig 9. Injected tideglusib 
(i.p.)  decreases 
consumption and shows a 
downward trend in 
preference (van der Vaart, 
2018).
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